Novavax Plunges on 'Harsh' FDA Review Ahead of Tuesday Panel

Novavax Inc. slumped 20% on Friday after US regulators raised concerns over the biotech’s much-anticipated Covid-19 vaccine. Briefing documents released by the Food and Drug Administration ahead of a meeting with experts on Tuesday noted some heart risks with the shot, though the agency was positive on its effectiveness against the omicron variant and more severe disease.